Mesoblast (MESO) Share-based Compensation (2016 - 2025)
Mesoblast (MESO) posted Share-based Compensation of $791000.0 for Q1 2023, down 43.78% sequentially from $1.4 million in Q4 2022, and down 58.13% YoY from $1.9 million in Q1 2022.
Mesoblast (MESO) Share-based Compensation (2016 - 2025) Analysis & Trends
Mesoblast has reported Share-based Compensation for 8 years, with the latest figure at $791000.0 in Q1 2023.
- Quarterly Share-based Compensation fell 58.13% year-over-year to $791000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.6 million (down 44.14% YoY) and the FY2022 annual result came in at $5.5 million, down 55.75% from the prior year.
- Share-based Compensation declined to $791000.0 in Q1 2023 per MESO's latest filing, from $1.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.9 million in Q3 2020 and troughed at $350000.0 in Q3 2022.
- A 5-year average of $1.8 million and a median of $1.5 million in 2021 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2020 and 2021: Share-based Compensation surged 507.09% in 2020, then slumped 77.96% in 2021.
- Over 5 years, Share-based Compensation stood at $1.6 million in 2019, then soared by 115.46% to $3.5 million in 2020, then tumbled by 58.19% to $1.5 million in 2021, then decreased by 4.93% to $1.4 million in 2022, then plunged by 43.78% to $791000.0 in 2023.
- According to Business Quant data, Share-based Compensation over the past three periods registered $791000.0, $1.4 million, and $350000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | 15.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.17 Bn |
| Dec 31, 2025 | 15.17 Bn |
| Dec 31, 2024 | 15.17 Mn |
| Dec 31, 2024 | 15.17 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Mar 31, 2023 | 791,000.00 |
| Mar 31, 2023 | 791,000.00 |
| Dec 31, 2022 | 1.41 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 350,000.00 |
| Sep 30, 2022 | 350,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 1.48 Mn |
| Dec 31, 2021 | 1.48 Mn |
| Sep 30, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.08 Mn |